10-Q: Relay Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Relay Therapeutics reports a net loss of $88.1 million for the third quarter of 2024, while also announcing a strategic shift in its pipeline and plans to seek a commercialization partner for one of its lead assets.

Summary

• Relay Therapeutics reported a net loss of $88.1 million for the three months ended September 30, 2024, compared to a net loss of $65.7 million for the same period in 2023.
• The company's total revenue for the quarter was $0, a significant decrease from $25.2 million in the third quarter of 2023, primarily due to the termination of the Genentech collaboration.
• Research and development expenses were $76.6 million for the quarter, down from $81.5 million in the same period last year.
• General and administrative expenses increased to $19.8 million from $18.5 million year-over-year.
• The company's cash, cash equivalents, and investments totaled $839.6 million as of September 30, 2024.
• Relay Therapeutics believes its current cash position will fund operations into the second half of 2027.
• The company completed a public offering in September 2024, raising $218.2 million in net proceeds.
• The company announced plans to seek a global commercialization partner for lirafugratinib (RLY-4008) to focus on the rest of its portfolio.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has a strong cash position and has successfully raised capital, the loss of revenue from the Genentech collaboration and the increased net loss are concerning. The decision to seek a commercialization partner for lirafugratinib also suggests a shift in strategy that may not be viewed positively by investors. Overall, the sentiment is cautiously negative.

Positives

• The company's cash position of $839.6 million is expected to fund operations into the second half of 2027.
• The company successfully raised $218.2 million through a public offering in September 2024.
• Research and development expenses decreased slightly year-over-year, indicating some cost management.

Negatives

• The company's revenue decreased significantly due to the termination of the Genentech collaboration.
• The net loss for the quarter increased to $88.1 million from $65.7 million in the same period last year.
• The company is seeking a commercialization partner for lirafugratinib, indicating a shift in strategy and potentially reduced control over the asset.

Risks

• The company has a limited operating history and has incurred significant losses since inception.
• The company is dependent on third parties for clinical trials and manufacturing.
• The company faces substantial competition in the biopharmaceutical industry.
• The company's product candidates may not receive regulatory approval or achieve commercial success.
• The company may need to raise additional capital in the future, which may not be available on acceptable terms.
• The company's reliance on single-source suppliers for key materials poses a risk to its supply chain.
• The company's intellectual property may not be adequately protected or may be challenged by third parties.
• The company's operations are subject to various laws and regulations, including those related to data privacy and security.
• The company's stock price has been volatile and may continue to be so.

Future Outlook

The company believes its current cash position will fund operations into the second half of 2027. Relay Therapeutics plans to seek a global commercialization partner for lirafugratinib to focus on the rest of its portfolio.

Management Comments

• The company is focused on using the novel insights derived from its approach to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of our therapies.
• The company believes that while the interim clinical data from the ReDiscover Trial disclosed to date are preliminary, the data suggest interim efficacy signals in the patient population defined above, and support selective target engagement across doses and mutation types with an encouraging interim safety and tolerability profile.
• The company believes that while the interim clinical data from the ReFocus Trial disclosed to date are preliminary, the data show interim efficacy signals in the CCA pan-FGFR, or FGFRi, treatment-nave, FGFR2-fusion CCA cohort and non-CCA solid tumor expansion cohorts and further support our hypothesis that selective inhibition of FGFR2 can improve the treatment for patients with FGFR2-driven tumors.

Industry Context

The biopharmaceutical industry is highly competitive, with numerous companies developing therapies for cancer and genetic diseases. Relay Therapeutics is focused on precision medicine, using computational and experimental technologies to discover and develop new drugs. The termination of the Genentech collaboration and the decision to seek a commercialization partner for lirafugratinib reflect the challenges and strategic shifts that are common in this industry.

Comparison to Industry Standards

• Relay Therapeutics' cash burn rate is typical for a clinical-stage biotech company, but the decrease in revenue due to the Genentech termination is a significant setback.
• The company's R&D spending is in line with industry averages for companies at a similar stage of development, but the need to seek a commercialization partner for lirafugratinib may indicate a lack of internal resources or expertise for late-stage development and commercialization.
• The company's focus on precision medicine and its Dynamo platform are differentiating factors, but the success of these approaches remains to be seen in late-stage clinical trials and commercialization.
• Compared to companies like Blueprint Medicines or Loxo Oncology, which have successfully commercialized targeted therapies, Relay Therapeutics is still in an earlier stage of development and faces significant execution risks.
• The company's decision to seek a commercialization partner for lirafugratinib is similar to strategies employed by other biotech companies that focus on early-stage development and then partner with larger pharmaceutical companies for late-stage development and commercialization.

Stakeholder Impact

• Shareholders may be concerned about the decreased revenue and increased net loss.
• Employees may be affected by the strategic shift and potential changes in the company's focus.
• Patients may be impacted by the company's decision to seek a commercialization partner for lirafugratinib, which could affect the timeline for its availability.
• Suppliers and creditors may be affected by the company's financial performance and strategic decisions.

Next Steps

• The company will continue clinical trials for RLY-2608.
• The company will seek a global commercialization partner for lirafugratinib.
• The company will continue to advance its other preclinical programs.

Key Dates

Keywords

biopharmaceutical, clinical trials, drug development, precision medicine, oncology, genetic disease, RLY-2608, lirafugratinib, RLY-4008, financial results, research and development, regulatory approval, commercialization, capital raise